> Detailanzeige

Ivanoff, Sarah; Gruson, Berengere; Chantepie, Sylvain P.; Lemasle, Emilie; Merlusca, Lavinia; Harrivel, Veronique; Charbonnier, Amandine; Votte, Patrick; Royer, Bruno; Marolleau, Jean‐Pierre

5‐Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: 5‐Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy
  • Beteiligte: Ivanoff, Sarah; Gruson, Berengere; Chantepie, Sylvain P.; Lemasle, Emilie; Merlusca, Lavinia; Harrivel, Veronique; Charbonnier, Amandine; Votte, Patrick; Royer, Bruno; Marolleau, Jean‐Pierre
  • Erschienen: Wiley, 2013
  • Erschienen in: American Journal of Hematology
  • Sprache: Englisch
  • DOI: 10.1002/ajh.23464
  • ISSN: 0361-8609; 1096-8652
  • Schlagwörter: Hematology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>Despite progress in the understanding of leukemia pathophysiology, the treatment of acute myeloid leukemia (AML) remains challenging. In patients with refractory or relapsed (R/R) AML, the prognosis is still poor and this group is targeted for new drug development. We reviewed the outcome of 47 patients, with R/R AML after at least one course of intensive chemotherapy, treated with 5‐azacytidine in three different French institutions. The overall response rate was 38% including complete remission in 21%, partial remission in 11%, and hematological improvement in 6% of cases. Median time to relapse was 6 (range, 1–39) months. Median overall survival was 9 months (not reached by responders vs. 4.5 months for nonresponders patients, <jats:italic>P</jats:italic> = 0.0001). Univariate analysis identified the absence of peripheral blood blasts and &lt;20% bone marrow blasts as prognostic factors for both overall response and survival, but not age, ECOG/PS, type of AML, cytogenetic, status of the disease, number of previous lines of therapy, previous hematological stem cell transplantation, or white blood cells count. Bone marrow blasts percentage &lt;20% was the only independent prognostic factor identified by multivariate analysis for overall response (<jats:italic>P</jats:italic> = 0.0013) and survival (<jats:italic>P</jats:italic> = 0.0324). Six patients in remission could proceed to an allogenic hematological stem cell transplantation. The drug‐related grade 3/4 adverse events were hematopoietic toxicities (38%) and infection (32%). In conclusion, this study suggests that a salvage therapy with 5‐azacytidine is an interesting option for patients with R/R AML after intensive chemotherapy. Prospective randomized studies are needed to demonstrate a superiority of this approach over others strategies. Am. J. Hematol. 88:601–605, 2013. © 2013 Wiley Periodicals, Inc.</jats:p>
  • Zugangsstatus: Freier Zugang